MerLion's finafloxacin progresses for severe infections after positive IV results
This article was originally published in Scrip
Early clinical results with an intravenous formulation of MerLion Pharmaceuticals' finafloxacin indicate good potential for the use of the novel fluoroquinolone antibacterial in critical care settings, and further studies in severe, hospital-treated bacterial infections are now getting underway.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.